Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes-Reference-Cited by-同舟云学术

Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes

Published:2017-03 Issue: Volume:241 Page:41-45
ISSN:0166-0934
Container-title:Journal of Virological Methods
language:en
Short-container-title:Journal of Virological Methods

Author:

Wallis Carole L,Viana Raquel V,Saravanan Shanmugam,Silva de Jesus Carlos,Zeh Clement,Halvas Elias K,Mellors John W.

Publisher

Elsevier BV

Subject

Virology

Reference10 articles.

1. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort;Boulle;Antivir. Ther.,2007

2. Raltegravir: a new antiretroviral class for salvage therapy;Cahn;Lancet,2007

3. Adverse effects of antiretroviral therapy;Carr;Lancet,2000

4. Expanded access drug profile: raltegravir (RAL, MK-0518);Colquitt;Hopkins HIV Rep.,2007

5. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial;Grinsztejn;Lancet,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection;Clinical Infectious Diseases;2022-09-22

2. A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT);Microbiology Spectrum;2022-06-29

3. Development of a new comprehensive HIV-1 genotypic drug resistance assay for all commercially available reverse transcriptase, protease and integrase inhibitors in patients infected with group M HIV-1 strains;Infection, Genetics and Evolution;2020-07